Precision
Dutasteride
Designed to strongly inhibit scalp 5α-reductase while minimizing systemic absorption.
- 1Dutasteride inhibits both type I and type II isoenzymes for powerful suppression of scalp DHT.
- 2Anagen's proprietary delivery vehicle causes liposomes to preferentially aggregate in a follicular reservoir for localized diffusion to dermal papilla cells.
- 3At our new 1% dose, an early two-person blood check found serum dutasteride below the assay's limit of quantification.
Why we deliver through the follicle.
Dutasteride is one of the most potent DHT blockers there is, but its target sits deep inside the follicle, and taken orally it suppresses DHT across the whole body. The entire job of a topical is to put that potency at the follicle and minimize systemic absorption. That's a delivery problem, and it's the one Precision Dutasteride's vehicle is built to solve.
- 1The target is deep and local. Inside the follicle, 5α-reductase converts testosterone into DHT, and DHT acts on the dermal papilla at the base of the follicle to miniaturize it. The drug has to reach the dermal papilla, locally, deep in the follicle.
- 2Flat skin blocks the way. The stratum corneum, the skin's outer "brick-and-mortar" layer (keratin cells packed in a lipid matrix), is the rate-limiting barrier to topical drugs; intact lipid vehicles essentially can't cross it.
- 3The follicle is the shortcut. The follicle opening bypasses that barrier: the drug and its lipid vesicles funnel down the follicular canal and pool in the sebum as a long-lived "follicular reservoir": reaching depth, and lingering, in a way flat-skin diffusion can't.
- 4A localized gradient does the targeting. Concentrating the drug in the follicle builds a steep local concentration gradient. By Fick's law, diffusion flows from high to low concentration: a strong push across the thin canal wall into the dermal papilla, exactly where it's needed. Because the depot is small and local, the outward gradient is weak, so little drug spreads to the deeper dermis or the bloodstream.
That is the whole rationale for follicular targeting: the local action of dutasteride with far less of the systemic trade-off. Which is why we screened dozens of vehicles for exactly this property, and the rest of this page is the evidence the vehicle actually does it.
More than 60 delivery systems went in. One came out ahead.
A vehicle is only as good as where it puts the drug. We screened the field (liposomes, ethosomes, transfersomes, polymer nanospheres and nanocapsules, mineral carriers) for one property: routing dutasteride into the follicle.
Early Precision Dutasteride patients show no decrease in serum DHT.
If the drug truly stays local, systemic DHT should barely move. Across six early patients we monitored serum DHT (ng/dL) at baseline and follow-up. This is real-world observational monitoring (n = 6), not a randomized or controlled endpoint.
Minimal systemic DHT change, consistent with a follicle-local topical that leaves circulating hormone largely unmoved.
In skin tests, the drug concentrates in the follicle with variability between wet and dry scalp.
Targeting only matters if the drug also stays put. Ex vivo, dutasteride accumulated in the follicle while the deeper viable-skin compartment (the path toward circulation) stayed below the assay's detection limit. More dutasteride was recovered from the follicle in wet scalp conditions compared to dry.
We pushed the dose to 1%. Serum dutasteride stayed below what the assay can measure.
Ex vivo, the vehicle keeps dutasteride in the follicle and the systemic route reads empty (Plate 04). The real test is a person, at a high dose. Two of us applied 1 mL of the 1% formulation to the scalp once daily for four days, with serum dutasteride measured by LC-MS/MS before the first dose and after the fourth. The assay's limit of quantification was 0.1 ng/mL, run with a standard curve and QCs.
All four samples came back below the assay's floor, hundreds of times under the ≈ 40 ng/mL an oral dutasteride pill puts in your blood. The damp-scalp reading ticked up and the dry one didn't, echoing the wet-beats-dry uptake we saw ex vivo (Plate 04). But both stayed below quantification, so that gap is noise. Suggestive, not proof.
To move DHT, dutasteride has to be in your blood. The 0.5 mg pill that drops serum DHT about 90% runs near 40 ng/mL, roughly 400 times our assay's floor and far above anything we measured. Even a 0.01 mg dose, the lowest in the dose-ranging studies, leaves serum dutasteride below detection. So under 0.1 ng/mL is well beneath what it takes to move circulating DHT, which is why serum DHT didn't budge in our early monitoring (Plate 03). We don't give a hard cutoff because there isn't one: dutasteride binds 5α-reductase for good, so the effect follows enzyme turnover, not a single blood level.
Four days isn't steady state, so what if Participant 1 keeps applying? Taken at face value, that one rising reading models to a plateau right around the assay's floor within two to three weeks. It's a model built on a number below quantification, so we read it as an upper bound, not a measurement.
Dutasteride's hair-growth efficacy as a dual 5α-reductase inhibitor is well established and covered in depth elsewhere. This page is about delivery: getting that established molecule into the follicle while minimizing systemic absorption.
Targeted vehicle
The winning vehicle routes drug into the follicle: 0.64 vs ≈ 0.47 for the best alternative.
Measured · ex vivoSerum DHT unmoved
Across 6 early patients, serum DHT showed no decrease (+10.6%); stays within range.
Observed · n = 6Stays in the follicle
Drug accumulates in the follicle; the deeper systemic route stayed below detection.
Measured · ex vivoBelow quantification at 1%
At our highest dose, serum dutasteride stayed below the assay's limit of quantification, before and after.
Observed · n = 2Dial the strength
0.03% and 0.3%, plus a new 1%. A clinician dials the local dose to the plan.
ProductThree strengths, one follicle-targeting vehicle.
Choose from 0.03%, 0.3%, and 1%. A licensed clinician decides which strength is right for you.
What this page can and can't support
- Vehicle data is ex-vivo follicular targeting: a delivery measure (where the drug goes), not clinical hair growth, and not serum-DHT suppression on its own.
- The serum-DHT set is observational (n = 6), not a controlled PK or hormone study; stable DHT is the expected result for a topical, not proof of efficacy.
- The 1% systemic check is a two-person pilot: every reading sat below the assay's limit of quantification (0.1 ng/mL). It shows no measurable systemic rise at a high dose, not a guarantee of zero absorption, and a larger sample is needed to confirm it.
- 0.3% serum-DHT monitoring is pending: we report only what we've measured, and Precision Dutasteride (0.3%) hormone data is not yet available.
- Prescription product, clinician-gated. Suitability is decided by a licensed clinician. This page is treatment science, not medical advice.
